Top 95 medical and healthcare startups in Boston
May 04, 2026
|
Like
22
1
Funding: $300M
Beeline Medicines is a biotechnology company that identifies and provides precise treatments to autoimmune inflammatory disorders.
Beeline Medicines is a biotechnology company that identifies and provides precise treatments to autoimmune inflammatory disorders.
2
Funding: $163M
AcuityMD is a targeting platform for medical device companies that automatically uncovers new opportunities and keeps track of existing users across each of the products you sell. Stop the manual research and data entry and start connecting with your future users.
AcuityMD is a targeting platform for medical device companies that automatically uncovers new opportunities and keeps track of existing users across each of the products you sell. Stop the manual research and data entry and start connecting with your future users.
3
Funding: $1.6B
Ginkgo Bioworks is the organism company. We design custom microbes for customers across multiple markets. We build our foundries to scale the process of organism engineering using software and hardware automation. Organism engineers at Ginkgo learn from nature to develop new organisms that replace technology with biology.
Ginkgo Bioworks is the organism company. We design custom microbes for customers across multiple markets. We build our foundries to scale the process of organism engineering using software and hardware automation. Organism engineers at Ginkgo learn from nature to develop new organisms that replace technology with biology.
4
Funding: $1.2B
Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics
Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics
5
Funding: $866M
Amwell is a telehealth platform that providers, insurers, patients, and innovators deliver more affordable, higher quality care.
Amwell is a telehealth platform that providers, insurers, patients, and innovators deliver more affordable, higher quality care.
6
Funding: $662.7M
Aura provides AI-powered security solutions that offer identity theft protection, credit monitoring, and online privacy for individuals.
Aura provides AI-powered security solutions that offer identity theft protection, credit monitoring, and online privacy for individuals.
7
Funding: $637M
Nimbus Therapeutics is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
Nimbus Therapeutics is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
8
Funding: $603.2M
Cardurion is a cardiovascular biotechnology company developing therapeutics for the treatment of heart failure and cardiovascular diseases.
Cardurion is a cardiovascular biotechnology company developing therapeutics for the treatment of heart failure and cardiovascular diseases.
9
Funding: $479.6M
Reify Health is a cloud-based software company that develops tools for the clinical trial ecosystem.
Reify Health is a cloud-based software company that develops tools for the clinical trial ecosystem.
10
Funding: $463.6M
Biofourmis is reinventing remote patient monitoring by detecting personalized patterns predictive of patient’s health deterioration
Biofourmis is reinventing remote patient monitoring by detecting personalized patterns predictive of patient’s health deterioration
11
Funding: $460M
Valo Health is a biotech company that is recreating the future of medicine. Valo is using computers to accelerate drug development while reducing the failure rate
Valo Health is a biotech company that is recreating the future of medicine. Valo is using computers to accelerate drug development while reducing the failure rate
12
Funding: $387.5M
Caresyntax is a digital surgery platform that uses proprietary software and AI to deliver actionable insights to improve patient outcomes.
Caresyntax is a digital surgery platform that uses proprietary software and AI to deliver actionable insights to improve patient outcomes.
13
Funding: $355.2M
PathAI's goal is to improve cancer diagnosis using artificial intelligence. PathAI’s services solve the most challenging pathology problems faced by the research and pharmaceutical industry.
PathAI's goal is to improve cancer diagnosis using artificial intelligence. PathAI’s services solve the most challenging pathology problems faced by the research and pharmaceutical industry.
14
Funding: $331M
Aktis Oncology develops radiopharmaceutical treatments for solid tumors.
Aktis Oncology develops radiopharmaceutical treatments for solid tumors.
15
Funding: $325M
Seaport Therapeutics operates as a clinical stage biopharmaceutical company.
Seaport Therapeutics operates as a clinical stage biopharmaceutical company.
16
Funding: $301.6M
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases such as Duchenne muscular dystrophy (DMD).
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases such as Duchenne muscular dystrophy (DMD).
17
Funding: $301.1M
Akili builds clinically-validated cognitive therapeutics, assessments, and diagnostics that look and feel like video games. It aims to develop a new type of electronic medicine that can be deployed remotely directly to any patient anywhere, prescribed and tracked by physicians, with the potential to be developed at a fraction of the cost of traditional medical approaches.
Akili builds clinically-validated cognitive therapeutics, assessments, and diagnostics that look and feel like video games. It aims to develop a new type of electronic medicine that can be deployed remotely directly to any patient anywhere, prescribed and tracked by physicians, with the potential to be developed at a fraction of the cost of traditional medical approaches.
18
Funding: $286.7M
Our pioneering, flexible diagnostic instrument and disposable cartridge system is designed for decentralised laboratory, point-of–care and other near-patient settings. It provides a fast, easy-to-use and accurate affordable solution to screening for the presence of STIs and HAIs, where rapid diagnosis is essential for effective treatment and control.
Our pioneering, flexible diagnostic instrument and disposable cartridge system is designed for decentralised laboratory, point-of–care and other near-patient settings. It provides a fast, easy-to-use and accurate affordable solution to screening for the presence of STIs and HAIs, where rapid diagnosis is essential for effective treatment and control.
19
Funding: $287M
Dewpoint Therapeutics is a biotech company which develop a drug platform that targets biomolecular condensates.
Dewpoint Therapeutics is a biotech company which develop a drug platform that targets biomolecular condensates.
20
Funding: $283.4M
Atea Pharmaceuticals is a biopharmaceutical company which is engaged in the acquisition, discovery and development of novel antiviral therapeutics.
Atea Pharmaceuticals is a biopharmaceutical company which is engaged in the acquisition, discovery and development of novel antiviral therapeutics.
21
Funding: $274.5M
Medically Home is a services company that supplies remote care technology for at-home acute care
Medically Home is a services company that supplies remote care technology for at-home acute care
22
Funding: $271.3M
Emulate creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health.
Emulate creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health.
23
Funding: $265.2M
Sophia Genetics aims to bring data analytics solutions to the market, to support healthcare professionals by maximizing the power of data-driven medicine. It achieves this mission through the adoption of SOPHiA AI, which is built using techniques such as statistical inference, pattern recognition, and machine learning.
Sophia Genetics aims to bring data analytics solutions to the market, to support healthcare professionals by maximizing the power of data-driven medicine. It achieves this mission through the adoption of SOPHiA AI, which is built using techniques such as statistical inference, pattern recognition, and machine learning.
24
Funding: $224M
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer.
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer.
25
Funding: $209M
Ikena Oncology is developing novel immunometabolic therapies. Its flagship drug IMG-007 is a monoclonal antibody against OX40 with an extended half-life (5 weeks) for patients with immunological, autoimmune and inflammatory diseases. IMG-007 contains a modified Fc region that blocks ADCC function, meaning signaling by activated T cells is weakened without destroying or depleting T cells. This solution has the potential to improve tolerability and increase the range of measurement, leading to the use of higher doses, increased efficacy and improved safety. The company's primary target is atopic dermatitis. In a proof-of-concept clinical trial in patients with moderate to severe atopic dermatitis, three doses of IMG-007 administered over a one-month period resulted in symptom reduction in the majority of patients. Ikena Oncology was acquired by ImageneBio
Ikena Oncology is developing novel immunometabolic therapies. Its flagship drug IMG-007 is a monoclonal antibody against OX40 with an extended half-life (5 weeks) for patients with immunological, autoimmune and inflammatory diseases. IMG-007 contains a modified Fc region that blocks ADCC function, meaning signaling by activated T cells is weakened without destroying or depleting T cells. This solution has the potential to improve tolerability and increase the range of measurement, leading to the use of higher doses, increased efficacy and improved safety. The company's primary target is atopic dermatitis. In a proof-of-concept clinical trial in patients with moderate to severe atopic dermatitis, three doses of IMG-007 administered over a one-month period resulted in symptom reduction in the majority of patients. Ikena Oncology was acquired by ImageneBio
26
Funding: $206.8M
Life Biosciences engages in advancing longevity research and entrepreneurial solutions to improve and extend healthy lives. We bring together scientists and investors to find innovative solutions and move them from the lab to the market to benefit all people.
Life Biosciences engages in advancing longevity research and entrepreneurial solutions to improve and extend healthy lives. We bring together scientists and investors to find innovative solutions and move them from the lab to the market to benefit all people.
27
Funding: $207M
Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing our proprietary RNA interference platform.
Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing our proprietary RNA interference platform.
28
Funding: $205M
Asimov programs living cells with genetic circuits. We partner with customers to create previously impossible biotechnologies.
Asimov programs living cells with genetic circuits. We partner with customers to create previously impossible biotechnologies.
29
Funding: $186.1M
Cohere Health is changing the way patients, physicians and health plans work together. Our collaboration platform improves patient and physician experience, increases quality and reduces total cost of care.
Cohere Health is changing the way patients, physicians and health plans work together. Our collaboration platform improves patient and physician experience, increases quality and reduces total cost of care.
30
Funding: $183.3M
Kyruus delivers search and scheduling solutions for health systems to match patients with the right providers across the access points.
Kyruus delivers search and scheduling solutions for health systems to match patients with the right providers across the access points.
31
Funding: $177M
Antares is a biotechnology company focused on developing transformational,medicines targeting validated cancer and other serious diseases.
Antares is a biotechnology company focused on developing transformational,medicines targeting validated cancer and other serious diseases.
32
Funding: $171M
OM1 is a leading healthcare technology company focused on providing outcomes measurement. We’ve built an intelligent data cloud to enable different healthcare stakeholders to cost-effectively access, analyze, and use outcomes data in a more robust, clinically meaningful, and precise way.
OM1 is a leading healthcare technology company focused on providing outcomes measurement. We’ve built an intelligent data cloud to enable different healthcare stakeholders to cost-effectively access, analyze, and use outcomes data in a more robust, clinically meaningful, and precise way.
33
Funding: $166.2M
Elucid enables precision medicine for cardiovascular disease by applying A.I to medical image analysis validated against true biology.
Elucid enables precision medicine for cardiovascular disease by applying A.I to medical image analysis validated against true biology.
34
Funding: $165M
Third Arc Bio is a biotech company developing multifunctional antibodies for inflammatory and immunology diseases.
Third Arc Bio is a biotech company developing multifunctional antibodies for inflammatory and immunology diseases.
35
Funding: $162.5M
Akouos is a new biotechnology company focused on restoring and preserving hearing.
Akouos is a new biotechnology company focused on restoring and preserving hearing.
36
Funding: $153M
Superluminal Medicines is a generative biological and chemical company accelerating new possibilities in drug discovery and development.
Superluminal Medicines is a generative biological and chemical company accelerating new possibilities in drug discovery and development.
37
Funding: $153M
PatientsLikeMe is a patient network and real-time research platform. Through the network, patients connect with others who have the same disease or condition and track and share their own experiences with the goal to improve outcomes.
PatientsLikeMe is a patient network and real-time research platform. Through the network, patients connect with others who have the same disease or condition and track and share their own experiences with the goal to improve outcomes.
38
Funding: $140M
Ottimo Pharma develops innovative cancer therapies using PD1-VEGFR2 antibodies.
Ottimo Pharma develops innovative cancer therapies using PD1-VEGFR2 antibodies.
39
Funding: $128M
Eleos Health is a mental health startup that focuses on using voice analysis and NLP to improve treatment outcomes and workflow efficiency.
Eleos Health is a mental health startup that focuses on using voice analysis and NLP to improve treatment outcomes and workflow efficiency.
40
Funding: $118M
Zoe is leading the world’s largest ongoing nutritional research project in collaboration with scientists from universities including Harvard, King's College London, Massachusetts General Hospital, Oxford and Stanford.
Zoe is leading the world’s largest ongoing nutritional research project in collaboration with scientists from universities including Harvard, King's College London, Massachusetts General Hospital, Oxford and Stanford.
41
Funding: $115M
Author Health provides care and treatment for Medicare Advantage recipients with substance use disorders and serious mental illness.
Author Health provides care and treatment for Medicare Advantage recipients with substance use disorders and serious mental illness.
42
Funding: $115M
resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. esTORbio’s lead program has demonstrated in several clinical trials, including a randomized, placebo-controlled trial, the potential to treat multiple diseases of aging for which there are no approved therapies.
resTORbio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. esTORbio’s lead program has demonstrated in several clinical trials, including a randomized, placebo-controlled trial, the potential to treat multiple diseases of aging for which there are no approved therapies.
43
Funding: $109M
Nido Biosciences develops new precision medicines for neurological diseases and takes aim at Kennedy’s disease, a rare degenerative disorder.
Nido Biosciences develops new precision medicines for neurological diseases and takes aim at Kennedy’s disease, a rare degenerative disorder.
44
Funding: $100.4M
Activ Surgical is building a hardware-agnostic platform to enable autonomous and collaborative surgery through the integration of computer vision, artificial intelligence and robotics.
Activ Surgical is building a hardware-agnostic platform to enable autonomous and collaborative surgery through the integration of computer vision, artificial intelligence and robotics.
45
Funding: $95M
CodaMetrix is building an AI-powered platform for healthcare revenue cycle management
CodaMetrix is building an AI-powered platform for healthcare revenue cycle management
46
Funding: $93.2M
Snap40 develops a device that monitors users via its single medical-grade wearable device, worn on the upper arm. This includes relative changes in systolic blood pressure, respiratory rate, heart rate, mobility, blood oxygen saturation, and temperature, as well as perspiration and movement levels.
Snap40 develops a device that monitors users via its single medical-grade wearable device, worn on the upper arm. This includes relative changes in systolic blood pressure, respiratory rate, heart rate, mobility, blood oxygen saturation, and temperature, as well as perspiration and movement levels.
47
Funding: $93.2M
The primary device of Current’s monitoring platform is an FDA-cleared upper-arm wearable that tracks skin temperature, pulse rate, oxygen saturation, movement and other metrics. It uses AI for precise early warning alerts.
The primary device of Current’s monitoring platform is an FDA-cleared upper-arm wearable that tracks skin temperature, pulse rate, oxygen saturation, movement and other metrics. It uses AI for precise early warning alerts.
48
Funding: $90M
Ascidian Therapeutics is a biotechnology company intended for medical use in medical and clinical gene therapy.
Ascidian Therapeutics is a biotechnology company intended for medical use in medical and clinical gene therapy.
49
Funding: $82M
Exsilio develops genomic therapeutics that introduce therapeutic genes into safe shelters within the DNA.
Exsilio develops genomic therapeutics that introduce therapeutic genes into safe shelters within the DNA.
50
Funding: $82.3M
Renovia is the maker of an FDA-cleared, app-based system for pelvic floor disorder management and therapy
Renovia is the maker of an FDA-cleared, app-based system for pelvic floor disorder management and therapy
